1. Establishing patient centric specifications for drug substance and drug product impurities;Bercu;J. Pharmaceut. Innov.,2019
2. Regulation (EC) no. 1907/2006 of the European parliament and of the Council of 18 December 2006 concerning the registration, evaluation, authorisation and restriction of chemicals (REACH);CEC;EU CEC Brussels,2006
3. Advancing internal exposure and physiologically-based toxicokinetic modeling for 21st-century risk assessments;Cohen Hubal;J. Expo. Sci. Environ. Epidemiol.,2019
4. Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities. EMA/CHMP/CVMP/SWP/169430/2012;EMA,2014
5. Management of organic impurities in small molecule medicinal products: Deriving safe limits for use in early development;Harvey;Regul. Toxicol. Pharmacol.,2017